- Home
- ENB vs SNY Comparison
ENB vs SNY Comparison
Compare ENB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENB
- SNY
- Stock Information
- Founded
- ENB 1949
- SNY 1994
- Country
- ENB Canada
- SNY France
- Employees
- ENB N/A
- SNY N/A
- Industry
- ENB Natural Gas Distribution
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- ENB Energy
- SNY Health Care
- Exchange
- ENB Nasdaq
- SNY Nasdaq
- Market Cap
- ENB 99.9B
- SNY 116.5B
- IPO Year
- ENB N/A
- SNY N/A
- Fundamental
- Price
- ENB $45.09
- SNY $48.32
- Analyst Decision
- ENB Buy
- SNY Buy
- Analyst Count
- ENB 1
- SNY 2
- Target Price
- ENB $67.00
- SNY $62.50
- AVG Volume (30 Days)
- ENB 3.6M
- SNY 2.0M
- Earning Date
- ENB 08-01-2025
- SNY 07-31-2025
- Dividend Yield
- ENB 4.29%
- SNY 3.31%
- EPS Growth
- ENB 1.87
- SNY 39.56
- EPS
- ENB 1.88
- SNY 5.45
- Revenue
- ENB $42,395,380,370.00
- SNY $48,817,552,946.00
- Revenue This Year
- ENB N/A
- SNY $3.39
- Revenue Next Year
- ENB $3.62
- SNY $7.05
- P/E Ratio
- ENB $23.96
- SNY $8.86
- Revenue Growth
- ENB 43.00
- SNY N/A
- 52 Week Low
- ENB $36.06
- SNY $45.80
- 52 Week High
- ENB $47.44
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- ENB 50.35
- SNY 45.01
- Support Level
- ENB $44.62
- SNY $47.87
- Resistance Level
- ENB $45.49
- SNY $48.80
- Average True Range (ATR)
- ENB 0.65
- SNY 0.58
- MACD
- ENB 0.09
- SNY 0.10
- Stochastic Oscillator
- ENB 78.68
- SNY 28.85
About ENB Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the us and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. The firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.